DGAP-News: Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)
DGAP-News: Proteo Biotech AG / Schlagwort(e): Studie
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin
in Coronary Bypass Surgery (EMPIRE Study)
11.12.2012 / 12:45
———————————————————————
Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in
Coronary Bypass Surgery (EMPIRE Study)
75% of patients enrolled – Approval for EMPIRE sub-study
Irvine, CA – Kiel, December 11, 2012 – Proteo, Inc. (OTCQB: PTEO) and its
